Regulus Therapeutics Inc (NASDAQ: RGLS) kicked off on Monday, down -5.04% from the previous trading day, before settling in for the closing price of $1.68. Over the past 52 weeks, RGLS has traded in a range of $0.83-$2.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -10.71% over the last five years. While this was happening, its average annual earnings per share was recorded -42.89%. With a float of $53.18 million, this company’s outstanding shares have now reached $65.50 million.
The firm has a total of 34 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Regulus Therapeutics Inc (RGLS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regulus Therapeutics Inc is 19.71%, while institutional ownership is 63.67%. The most recent insider transaction that took place on Jan 30 ’25, was worth 54,260. In this transaction Chief Executive Officer of this company bought 50,000 shares at a rate of $1.09, taking the stock ownership to the 260,808 shares. Before that another transaction happened on Jan 30 ’25, when Company’s Director bought 19,610 for $1.06, making the entire transaction worth $20,787. This insider now owns 22,169 shares in total.
Regulus Therapeutics Inc (RGLS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -42.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 40.21% growth over the previous five years of trading.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
Take a look at Regulus Therapeutics Inc’s (RGLS) current performance indicators. Last quarter, stock had a quick ratio of 10.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
Analysing the last 5-days average volume posted by the [Regulus Therapeutics Inc, RGLS], we can find that recorded value of 1.16 million was better than the volume posted last year of 1.09 million. As of the previous 9 days, the stock’s Stochastic %D was 54.49%. Additionally, its Average True Range was 0.20.
During the past 100 days, Regulus Therapeutics Inc’s (RGLS) raw stochastic average was set at 63.11%, which indicates a significant increase from 42.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 121.98% in the past 14 days, which was higher than the 89.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3513, while its 200-day Moving Average is $1.5361. Now, the first resistance to watch is $1.7300. This is followed by the second major resistance level at $1.8600. The third major resistance level sits at $1.9500. If the price goes on to break the first support level at $1.5100, it is likely to go to the next support level at $1.4200. Should the price break the second support level, the third support level stands at $1.2900.
Regulus Therapeutics Inc (NASDAQ: RGLS) Key Stats
The company with the Market Capitalisation of 105.99 million has total of 66,243K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -46,360 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -12,790 K.
